Purple Biotech Ltd. (PPBT)

IL — Healthcare Sector
Peers: PLUR  BLRX  ARDS  ENLV  ANEB  PMVP  MIRO  ZIVO  BNOX  BPTH  ENDV  CING  SLNO    CINGW  SABS  CVKD  MNPR 

Automate Your Wheel Strategy on PPBT

With Tiblio's Option Bot, you can configure your own wheel strategy including PPBT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PPBT
  • Rev/Share 0.0
  • Book/Share 0.9498
  • PB 0.0072
  • Debt/Equity 0.0056
  • CurrentRatio 2.2343
  • ROIC -0.3644

 

  • MktCap 1820256.7393
  • FreeCF/Share -0.4146
  • PFCF -0.1267
  • PE -0.0329
  • Debt/Assets 0.0049
  • DivYield 0
  • ROE -0.2362

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
PPBT
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal from June 16-19, 2025.

Read More
image for news Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
Purple Biotech Reports First Quarter 2025 Financial Results
PPBT
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025

Read More
image for news Purple Biotech Reports First Quarter 2025 Financial Results
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
PPBT
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction

Read More
image for news Purple Biotech Appoints Shai Lankry as Chief Financial Officer
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
PPBT
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)

Read More
image for news Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

About Purple Biotech Ltd. (PPBT)

  • IPO Date 2015-11-20
  • Website https://purple-biotech.com
  • Industry Biotechnology
  • CEO Michael Schickler
  • Employees 9
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.